drugset / Trial / NCT03467217
Losartan for the Treatment of Pediatric NAFLD
Phase 2
Terminated
83 enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Johns Hopkins University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).
Timeline
- Start
- 2018-10-02
- Primary completion
- 2020-06-30
- Completion
- 2020-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Losartan | Other / unclassified | 100 mg | Oral |